The broadest view of post-mortem brains in Alzheimer’s disease (AD) has unveiled the genome, transcriptome and epigenome alterations of this neurodegenerative condition. The coordinated research, directed by scientists at the Massachusetts Institute of Technology (MIT), also described new cellular pathways that could help the scientific community design new therapies. Four simultaneous studies published on Sept. 28, 2023, in Cell, presented a brain single-cell atlas of AD, exposed the damage that affects DNA, and described the processes that alter the microglia and dysregulate the epigenome. Read More
Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a pore-forming protein secreted by Listeria monocytogenes to escape lysosomes. Read More
Sosei Group Corp. and Verily Life Sciences LLC, an Alphabet company, have announced the successful validation and nomination of a first G protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD). Read More
A presentation given recently by Medicenna Therapeutics Corp. highlighted preclinical data for the company’s new anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy) candidate, MDNA-223, being developed as a anticancer therapeutic candidate. Read More
Customer feedback is critical so that we can make BioWorld Science an even more useful and valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take less than 5 minutes. You can click through to the question here. Read More
Ionis Pharmaceuticals Inc. has announced its intention to advance four new wholly owned neurology medicines into the clinic by the end of next year. Read More
Scorpion Therapeutics Inc. has disclosed tetrahydroindole derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer. Read More
The activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is key for antitumor immunity. However, the development of STING agonist-based strategies in cancer has so far encountered limitations such as incomplete tumor regression or adverse effects derived from chronic activation. Read More
Researchers from Ascentage Pharma Group International and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized tricyclic compounds acting as inhibitor of apoptosis proteins (IAP) inhibitors reported to be useful for the treatment of cancer, AIDS, autoimmune disease, immune thrombocytopenia (idiopathic thrombocytopenic purpura), infections, psoriasis, rheumatoid arthritis, and inflammatory disorders, among others. Read More
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co Ltd. have identified heterocyclic derivatives acting as Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of melanoma, Menkes disease, rheumatoid arthritis, atherosclerosis, type 1 diabetes, Huntington’s disease and Alzheimer’s disease. Read More
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, has awarded Vir Biotechnology Inc. approximately $50 million in new funding to advance the development of novel monoclonal antibody (MAb) candidates and delivery solutions to widen the applicability of MAbs in COVID-19 and in pandemic preparedness and response. Read More
Astellas Pharma Inc. has divulged proteolysis targeting chimera (PROTAC) compounds acting as GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer. Read More
Merck Sharp & Dohme Ltd. has described ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors reported to be useful for the treatment of cancer, Lewy body dementia, diabetes, obesity, polycystic kidney disease, neurodegeneration, lysosomal storage disease and Parkinson’s disease, among others. Read More
Iambic Therapeutics Inc. (formerly Entos Inc.) has closed a $100 million series B financing. The company intends to use this funding to support continued artificial intelligence (AI) platform innovations and advance candidates into clinical development. Read More
Aerium Therapeutics Inc. has licensed and commenced development of three monoclonal antibodies (MAbs) with broad and potent activity against the predominant variants of SARS-CoV-2, including those containing the F456L mutation, such as EG.5.1. These antibodies could provide an option to protect immunocompromised populations from severe COVID-19. Read More
